Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.40 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.35 |
| ▸ | XDH | P47989 | 1/20 | 0.35 |
| ▸ | HMGCR | P04035 | 1/20 | 0.35 |
| ▸ | ACLY | P53396 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16632472 | 0.91 | TRPV3 (0.39) | TRPV3PTGER1NR1H2CYP2C9TLR9 | |
| SCHEMBL16632441 | 0.90 | TRPV3 (0.45) | TRPV3NR1H2TLR9TLR7NR1H3 | |
| SCHEMBL16632508 | 0.85 | NR1H2 (0.36) | NR1H2NR1H3MDM2 | |
| SCHEMBL16632578 | 0.76 | TRPV3 (0.47) | TRPV3PTGER1NR1H2CYP2C9TLR9 | |
| SCHEMBL16632686 | 0.75 | NR1H2 (0.36) | NR1H2NR1H3 | |
| SCHEMBL16632645 | 0.74 | NR1H2 (0.40) | TRPV3NR1H2NR1H3 | |
| SCHEMBL16632914 | 0.72 | PTGER1 (0.45) | TRPV3PTGER1CYP2C9MRGPRX4 | |
| SCHEMBL27683747 | 0.71 | EDNRA (0.41) | TRPV3PTGER1NR1H2NR1H3MRGPRX4 | |
| SCHEMBL16632576 | 0.70 | NR1H2 (0.41) | TRPV3PTGER1NR1H2CYP2C9TLR9 | |
| SCHEMBL16632521 | 0.70 | TRPV3 (0.41) | TRPV3TLR9TLR7MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9382245-B2 | Compounds and methods for treating HIV infections | YALE UNIVERSITY (US) | 2016-07-05 | — | — | US | disclosed |
| US-20150105351-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105351-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS | POLM, POLRMT, DHFR | TRPV3 4220/4885PTGER1 2498/4885NR1H2 1253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.